Stock KNSA KINIKSA PHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
20.08 USD +3.61% Intraday chart for Kiniksa Pharmaceuticals, Ltd. +12.30% +14.48%
Apr. 23 Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises MT
Apr. 23 Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024

Evolution of the average Target Price on Kiniksa Pharmaceuticals, Ltd.

Price target over the last 5 years

History of analyst recommendation changes

07fc44ccad00b24f.T_D--fP0NeCnAZqvJ2r9BxOFbTUu2kU2NTGwoc8v7Jw.PLuslZKsU6v_d_HqXjW3UXWxAEZErwpbWkTx86cblf02nsi3lLdRl4p57Q~29fed3844a65c578ce82df2ca8b2360c

Analyst Recommendations on Kiniksa Pharmaceuticals, Ltd.

Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating MT
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating MT
Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating MT
JPMorgan Adjusts Kiniksa Pharmaceuticals' Price Target to $20 From $19, Keeps Overweight Rating MT
Wedbush Lowers Kiniksa Pharmaceuticals' Price Target to $20 From $26, Adjusts Commercial Ramp Assumptions for Arcalyst; Keeps Outperform Rating MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $26 From $25, Keeps Outperform Rating MT
Wedbush Lifts Price Target for Kiniksa Pharmaceuticals to $25 From $24, Maintains Outperform Rating MT
Wedbush Lowers Price Target for Kiniksa Pharmaceuticals to $24 From $28, Maintains Outperform Rating MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $28 From $25.91; Outperform Rating Kept MT
BofA Securities Adjusts Kiniksa Pharmaceuticals' Price Target to $34 From $37, Reiterates Buy Rating MT
JPMorgan Adjusts Price Target on Kiniksa Pharmaceuticals to $27 From $30, Reiterates Overweight Rating MT
Wedbush Lifts Kiniksa Pharmaceuticals' Price Target to $26 From $24; Outperform Rating Kept MT
KINIKSA PHARMACEUTICALS : Wedbush Cuts Price Target on Kiniksa Pharmaceuticals to $24 From $32, Citing Vixarelimab Launch Timeline; Outperform Rating Kept MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $32 From $35 on Estimated Mavrilimumab Launch Date; Outperform Rating Kept MT
KINIKSA PHARMACEUTICALS : Evercore ISI Starts Kiniksa Pharmaceuticals at Outperform with $25 Price Target MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $35 From $38, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.08 USD
Average target price
30 USD
Spread / Average Target
+49.40%
High Price Target
32 USD
Spread / Highest target
+59.36%
Low Price Target
28 USD
Spread / Lowest Target
+39.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kiniksa Pharmaceuticals, Ltd.

Wedbush
JPMorgan Chase
BofA Securities

Ratings for Kiniksa Pharmaceuticals, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KNSA Stock
  4. Consensus Kiniksa Pharmaceuticals, Ltd.